No Buyout for You. (Yet.)

Achillion Pharmaceuticals' (Nasdaq: ACHN  ) chief medical officer resigned and shares in the biotech fell 4% yesterday. Was Elizabeth Olek really that important to the organization? I don't think so.

If anything, you'd think her leaving was a good thing. As you'll recall, the company kind of bungled its presentation of data of its hepatitis C drug ACH-1625 at the annual meeting  of the European Association for the Study of the Liver. Who knows whether it was really Olek's fault, but the buck stops with the chief medical officer.

The company didn't say the reason she was leaving, but this could certainly be a situation of an executive quitting to avoid being let go. Milind Deshpande, current president of research and development and chief scientific officer, will take over clinical trial operations for the company's hepatitis C program.

If Achillion is better off with Olek -- or at least not any worse off -- then why did the stock fall? My guess is investors hoping for a buyout came to a realization that it isn't going to happen anytime soon.

Since Gilead Sciences (Nasdaq: GILD  ) bought Pharmasset and Bristol-Myers Squibb bought Inhibitex, the remaining small hepatitis C drug developers have been trading with a premium added to their price in expectation of a buyout. Like HIV, hepatitis C is treated with a cocktail of drugs. Partnerships are possible, but having full control of compounds in different classes makes it easier to develop a cocktail.

If a buyout was imminent, there'd be no reason for Olek and Achillion to part company. Achillion wouldn't need to demand her resignation, if that's what happened, and Olek certainly wouldn't want to leave, potentially giving up stock options and other incentives that might vest upon an acquisition.

The moral of the story here is that investors shouldn't buy in hopes of a buyout. Sure Vertex Pharmaceuticals (Nasdaq: VRTX  ) or Merck (NYSE: MRK  ) or one of the other players could decide it needs to fill a hole. One of the drugs from the frontrunners -- Gilead, Bristol, and Abbott Labs (NYSE: ABT  ) -- could fail. But that's a really poor investment thesis.

Fool co-founder David Gardner and his team at Rule Breakers aren't counting on an acquisition to get solid returns from one of their recent health-care picks. Find out what it is and why they like it in the Fool's free report "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1907604, ~/Articles/ArticleHandler.aspx, 9/21/2014 12:04:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement